1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Urologix, Inc.

Urologix, Inc.

ULGX
Urologix, Inc.US flagOther OTC
0.00
USD
- -
- -
2,182.00Market Cap
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
TTM
Revenue per Share
1.65
1.35
1.74
1.81
1.81
1.49
1.04
0.89
1.02
0.86
1.16
0.8
0.67
0.56
Basic EPS, GAAP
-0.12
-0.74
0.03
0.2
0.38
-0.92
-1.04
-0.31
-0.15
-0.26
-0.32
-0.21
-0.36
-0.22
Free Cash Flow per Basic Share
-0.21
-0.56
0.2
0.2
0.01
0.08
-0.09
-0.28
-0.09
-0.18
-0.05
-0.1
-0.07
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-5.04
-5.72
-5.69
-5.39
-4.99
-5.91
-6.94
-7.19
-7.32
-7.55
-7.77
-5.74
-5.96
-5.9
Tangible Book Value per Share
1.37
0.7
0.8
1.06
1.59
1.21
0.95
0.68
0.56
0.33
-0.32
-0.2
-0.39
-0.43
Basic Weighted Avg Shares
14
14
14
14
14
14
14
14
15
15
15
21
21
22
Sales/Revenue/Turnover
23
19
24
26
26
21
15
13
15
13
17
17
14
12
Operating Margin (%)
-8.29
-47.38
1.58
12.1
2.97
-41.9
-112.69
-34.84
-15.28
-29.64
-24.34
-27.31
-28.09
-8.24
Depreciation Expense
2
2
2
2
2
2
1
1
1
1
1
1
1
1
Net Income, GAAP
-2
-10
- -
3
5
-13
-15
-4
-2
-4
-5
-4
-8
-5
Effective Tax Rate (%)
- -
2.85
44.55
13
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-7.26
-55.04
1.46
10.99
21.22
-62.1
-99.94
-34.48
-14.68
-29.7
-27.57
-25.87
-53.45
-38.29
Working Capital
14
4
9
13
17
16
11
8
7
4
-2
3
-1
-3
LT Debt
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
5
4
Total Equity
39
29
30
33
40
28
14
10
8
5
1
- -
-7
-8
Return on Invested Capital (%)
- -
-24.55
0.71
8.6
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
14.08
-0.45
-3.62
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'15
Dec'15
Mar'15
ST Debt
1
1
2
LT Borrowings
5
5
4
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
2
2
2

Working Capital

FRC

•

in mil. unless spec.
Sep'15
Dec'15
Mar'15
Total Current Assets
4
4
3
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
2
1
1
Inventories
1
1
1
Total Current Liabilities
4
5
6
Payables & Accruals
2
2
2
ST Debt
1
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-201.68%
-387.89%
-1,761.19%
Free Cash Flow
47.94%
20.9%
-24.06%
Net Income, GAAP
50.75%
23.13%
77.26%
Sales/Revenue/Turnover
-3.63%
3.81%
-14.2%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
4
4
4
4
17
2014
4
4
3
3
14
2015
3
3
3
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
-0.05
-0.05
-0.05
-0.06
-0.21
2014
-0.06
-0.05
-0.08
-0.17
-0.36
2015
-0.02
-0.02
-0.02
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Bryon Merade
Full Time Employees
61
Sector
Healthcare
Industry
Medical - Devices
Address
14405 21st Avenue North Minneapolis MN United States of America 55447
IPO Date
May 30, 1996
CIK
0000882873
Website
urologix.com
Similar Companies
Drägerwerk AG & Co. KGaA (DRW3.DE)
Deltex Medical Group plc (DEMG.L)
Belluscura plc (BELL.L)
ENvizion Medical Ltd. (ENVM.TA)
Episurf Medical AB (EPIS-B.ST)
Acutus Medical, Inc. (AFIB)
Business
Urologix, Inc. (ULGX) develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy (CTT), which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort; and Prostiva RF Therapy System, which delivers radio frequency energy directly into the prostate to destroy excess tissue, reduce urethral constriction, and relieve BPH symptoms. Urologix, LLC serves urologists and patients seeking office-based alternatives to medication or surgery, with operations focused on the U.S. market. Founded in 1991 and headquartered in Minneapolis, Minnesota, the company emphasizes safe, durable in-office therapies that demonstrate long-term efficacy, including symptom score and flow rate improvements in over 90% of CTT patients and 86% of Prostiva patients through five years. In 2016, Urologix sold most operating assets to a private buyer to settle debt with Medtronic, transitioning to private ownership as Urologix, LLC while retaining Plymouth, Minnesota operations and continuing to provide Cooled ThermoTherapy and Prostiva RF Therapy without customer disruption; no major acquisitions, funding rounds, partnerships, or product launches have been reported since.